Analyst Price Targets — BMY
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 8, 2026 11:33 am | — | Cantor Fitzgerald | $54.00 | $59.20 | TheFly | Bristol Myers price target raised to $54 from $45 at Cantor Fitzgerald |
| March 6, 2026 12:44 pm | Michael Yee | UBS | $70.00 | $59.79 | StreetInsider | Bristol-Myers Squibb Co. (BMY) PT Raised to $70 at UBS Ahead of Major Catalyst |
| February 24, 2026 9:03 pm | Trung Huynh | RBC Capital | $60.00 | $61.60 | StreetInsider | RBC Capital Starts Bristol-Myers Squibb Co. (BMY) at Sector Perform |
| February 23, 2026 11:32 am | — | Piper Sandler | $75.00 | $60.66 | TheFly | Bristol Myers price target raised to $75 from $66 at Piper Sandler |
| February 19, 2026 9:15 pm | — | Barclays | $75.00 | $60.30 | TheFly | Bristol Myers initiated with an Overweight at Barclays |
| February 6, 2026 3:41 pm | Terence Flynn | Morgan Stanley | $40.00 | $61.86 | TheFly | Bristol Myers price target raised to $40 from $37 at Morgan Stanley |
| February 6, 2026 12:22 pm | — | Guggenheim | $72.00 | $59.52 | TheFly | Bristol Myers price target raised to $72 from $62 at Guggenheim |
| February 6, 2026 11:21 am | Mohit Bansal | Wells Fargo | $60.00 | $59.52 | TheFly | Bristol Myers price target raised to $60 from $55 at Wells Fargo |
| January 28, 2026 11:42 am | — | Piper Sandler | $66.00 | $55.56 | TheFly | Bristol Myers price target raised to $66 from $62 at Piper Sandler |
| January 13, 2026 2:13 pm | David Risinger | Leerink Partners | $60.00 | $56.39 | TheFly | Bristol Myers price target raised to $60 from $54 at Leerink |
Latest News for BMY
Allspring Global Investments Holdings LLC grew its stake in shares of Bristol Myers Squibb Company (NYSE: BMY) by 5.5% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,095,654 shares of the biopharmaceutical company's stock after acquiring an additional 57,224 shares
Bristol Myers Squibb (BMY) reached $60.48 at the closing of the latest trading day, reflecting a +2.99% change compared to its last close.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Bristol Myers (BMY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.